# Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia

> **NCT07052838** · PHASE3 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Paroxysmal Nocturnal Haemoglobinuria (PNH)

## Interventions

- **DRUG:** HSK39297 tablets

## Key facts

- **NCT ID:** NCT07052838
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-12
- **Primary completion:** 2025-12-23
- **Final completion:** 2026-01-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07052838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07052838, "Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT07052838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*